MENLO PARK, California, November 19, 2021 / PRNewswire / – LevitasBio has announced the expansion of its product portfolio with the launch of two new product lines that will enable researchers and laboratory personnel to better process and characterize human, animal and plant samples. As is widely understood, optimal results from cell research will generally depend on the purity and viability of cells harvested from complex samples as a result of a series of disconnected, long, and disconnected processing and characterization steps. potentially difficult. High-value downstream assays, such as single cell sequencing or cell expansion-based workflows, such as cell line development, rely on gentle manipulation that minimizes cell disruption and maintains the native biology studied. . These new LevitasBio products will extend the new enrichment capabilities of the company’s existing LeviCell platform to further integrate and optimize the tissue dissociation and sample purification steps, even for the most difficult sample types, while maintaining maximum cell health and viability.
Optimized tissue dissociation reagents
Processing tissue samples, such as resections and biopsies, is the most vital step in sample preparation, but it is often the most technically difficult. As researchers aim to understand natural biological processes, it is essential to maintain the native cell populations of the original sample – without disturbance, disturbance, or capture bias – while ensuring target cell enrichment. LevitasBio’s new tissue dissociation kits are specifically optimized for existing LeviCell workflows, allowing smoother end-to-end manipulation on a wide range of human tissue types and models, including tumors, heart, liver, the lungs, kidneys and brain. The kits will allow customers to achieve high viability suspension cell enrichment while minimizing cell stress, damage or population bias.
Target exhaustion tests
While improving cell viability is generally an important goal for cell processing, researchers often also require the removal of specific cell types, extracellular matrix, or molecular background that may otherwise confuse downstream results. Examples may include removing immune cells from dissociated tumor biopsies, dissociated brain myelin, unperfused liver red blood cells, or extracellular RNA background free of any single cell assay preparation. New LevitasBio depletion assays remove specific and selectable background targets from the sample during LeviCell enrichment, allowing viable cell enrichment, debris removal and targeted background depletion in one step. This comprehensive workflow is a revolutionary approach to targeted sample enrichment, putting sample purity in the hands of the researcher.
“Our goal is to enable our customers to discover what is currently hidden in their samples,” explains Martin Piepryzk, CEO of LevitasBio, “By allowing researchers to access viable cells specifically enriched from starting samples. difficult while simultaneously characterizing the sample, opens the door to previously inaccessible discoveries. ”
“For us, the enrichment of next-generation samples already provided by our LeviCell platform is just the start,” adds Paul steinberg, CCO of LevitasBio, “We will continue to expand capabilities around the LeviCell platform to integrate and optimize the currently disparate sample processing and characterization workflows.”
Early access to new products is already provided to some customers and will be commercially available in the first half of 2022.
For more information on the expansion of LevitasBio’s portfolio, please visit www.levitasbio.com/horizon.
LevitasBio (www.LevitasBio.com) advances science and human health by providing researchers with a new and powerful method of cell enrichment and analysis. Equipped with our proprietary magnetic levitation technology, our laboratory instruments harness the power of levitation to detect, quantify, enrich and test cells accurately and smoothly. Our method is label-free and provides an unbiased method of detecting cell type and condition with minimal time and manipulation. Demonstrations of the patented technology have been published in the Proceedings of the National Academy of Sciences. New applications of our technology have already been demonstrated with a diverse group of partners, including CZ Biohub, Stanford University, and others.
Media contact details: